Brief: Treace Medical Q2 EPS USD -0.28

Treace Medical Concepts

07/08/2025 21:05

Overview

Treace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG data

Net loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%

Expanded bunion technology portfolio with new systems and increased patent holdings

Outlook

Treace reaffirms 2025 revenue guidance of $224 mln to $230 mln

Company expects breakeven Adjusted EBITDA for full-year 2025

Treace projects 50% reduction in cash usage for 2025

Result Drivers

TECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growth

OPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figures

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$47.39 mln
$47.10 mln (6 Analysts)
Q2 EPS
-$0.28
Q2 Gross Margin
79.7%
Q2 Gross Profit
$37.75 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.00, about 39.2% above its August 6 closing price of $5.47

Press Release: ID:nGNXbhyGfy

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)